Value_Investor
3 years ago
None of them as I can tell. Wow, SNNAQ (CH7-NON-CLEAN shell with 22,892,413 shares OS) had over $1.6M market value at 52-week-high $0.07 v.s. its "Q" peer ORMTQ (CH11-CLEAN shell with 18,662,272 shares Much-Smaller OS) only had $0.37M market value at 52-week-high $0.02!
Buying SNNAQ at most recent high $0.07 = buying ORMTQ at $0.0859 which is 5.824 Times of current price $0.01475!
Buying SNNAQ at most recent low $0.016 = buying ORMTQ at $0.0197 vs at $0.01475 now!
Buying ORMTQ at 52-week-high $0.02 = buying SNNAQ at $0.0163 vs at $0.025 now!
Buying ORMTQ at most recent low $0.0095 = buying SNNAQ at $0.0077 vs at $0.025 now!
Buying SNNAQ at last-Friday's high $0.03125 = buying ORMTQ at $0.0384 vs at $0.01475 now!
Buying SNNAQ at last-Friday's low $0.025 = buying ORMTQ at $0.0307 vs at $0.01475 now!
A CLEAN shell has Much Much Higher valuation than an NON-CLEAN shell! A CH11 shell has Much Higher valuation than a CH7 shell!
Therefore SNNAQ is Much Much More Expensive than ORMTQ now!
81vette
4 years ago
why would insiders buy> 02/22/2019 ARCH VENTURE PARTNERS X, LLC
Beneficial Owner (10%) Indirect Buy 2.50 2,165,800
02/22/2019 ARCH VENTURE PARTNERS VIII, LLC
Beneficial Owner (10%) Indirect Buy 2.50 2,165,800
02/22/2019 BUROW KRISTINA
Director Indirect Buy 2.50 2,165,800
02/22/2019 MORE ROBERT J
Director Direct Buy 2.50 100,000
02/22/2019 LEONARD KEITH R
Director Direct Buy 2.50 100,000
02/22/2019 BEDDINGFIELD III FREDERICK
Officer Direct Buy 2.50 40,000
420man
5 years ago
Delist Friday...wondering if the Q will be added as well...
Back to News Results
Sienna Biopharmaceuticals Will Be Delisted from Nasdaq -- Market Talk
11:57 am ET December 11, 2019 (Dow Jones) Print
1157 ET - Sienna Biopharmaceuticals has requested that Nasdaq delist the company's stock as of Friday. The clinical-stage biopharmaceutical company, which went public in 2017 and filed for chapter 11 bankruptcy protection in September, said Tuesday it will shut down by the end of the week. Sienna's stock was to remain conditionally listed on the Nasdaq pending the results of a sale process, which resulted in Sienna receiving approval to sell one of its topical medications to Sebacia Inc, a commercial-stage dermatology and aesthetics company, for about $1.7M. The company did not receive bids for any of its other assets. (aisha.al-muslim@wsj.com; @aishaalmuslim)
(END) Dow Jones Newswires
December 11, 2019 11:57 ET (16:57 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.